FCP
MRK icon

Fidelis Capital Partners’s Merck MRK Stock Holding History

Fidelis Capital Partners’s Portfolio MRK Stock Details MRK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.73M Sell
47,671
-1,447
-3% -$167K 0.41% 51
2025
Q4 		$5.17M Buy
49,118
+9,029
+23% +$848K 0.38% 57
2025
Q3 		$3.36M Buy
40,089
+3,804
+10% +$313K 0.26% 76
2025
Q2 		$2.88M Sell
36,285
-798
-2% -$63.4K 0.26% 73
2025
Q1 		$3.07M Sell
37,083
-9,488
-20% -$886K 0.33% 65
2024
Q4 		$4.65M Buy
46,571
+4,297
+10% +$443K 0.46% 46
2024
Q3 		$4.5M Buy
42,274
+1,298
+3% +$154K 0.54% 38
2024
Q2 		$4.61M Buy
40,976
+2,949
+8% +$380K 0.66% 30
2024
Q1 		$5.02M Buy
38,027
+4,640
+14% +$572K 0.76% 28
2023
Q4 		$3.64M Buy
33,387
+12,534
+60% +$1.3M 0.81% 24
2023
Q3 		$2.15M Buy
20,853
+1,186
+6% +$128K 0.73% 26
2023
Q2 		$2.27M Buy
19,667
+1,325
+7% +$150K 0.83% 24
2023
Q1 		$2.16M Buy
18,342
+7,792
+74% +$841K 0.92% 19
2022
Q4 		$1.16M Buy
+10,550
New +$1.08M 1.37% 17

Other funds holding MRK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fidelis Capital Partners's MRK Position: Q1 2026 in Review

Fidelis Capital Partners reduced its Merck (MRK) stake by 2.9% in Q1 2026, selling an estimated $167K and leaving 47,671 shares worth $5.73M. The position accounts for 0.41% of the portfolio, ranked #51.

Fidelis Capital Partners first reported a position in MRK in Q4 2022 and has held it in 14 quarters since. 3,778 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Fidelis Capital Partners held 47,671 shares of Merck worth $5.73M as of Q1 2026.
  • Fidelis Capital Partners sold 1,447 Merck shares in Q1 2026, an estimated $167K.
  • Merck made up 0.41% of Fidelis Capital Partners's portfolio in Q1 2026, its #51 holding.
  • Fidelis Capital Partners first reported a position in Merck in Q4 2022 and has held it in 14 quarters since.
  • 3,778 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Fidelis Capital Partners's 13F filing for Q1 2026, filed 6 May 2026.